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The role of the WDFY1 protein has been studied as a TLR3/4 scaffold/recruiting protein
in the immune system and in different oncogenic conditions. However, its function
in brain remains poorly understood. We have found that in mice devoid of Helios
(He−/− mice), a transcription factor specifically expressed during the development of
the immune cells and the central nervous system, there is a permanent and sustained
increase of Wdfy1 gene expression in the striatum and hippocampus. Interestingly,
we observed that WDFY1 protein levels were also increased in the hippocampus and
dorsolateral prefrontal cortex of schizophrenic patients, but not in the hippocampus of
Alzheimer’s disease patients with an associated psychotic disorder. Accordingly, young
He−/− mice displayed several schizophrenic-like behaviors related to dysfunctions in
the striatum and hippocampus. These changes were associated with an increase in
spine density in medium spiny neurons (MSNs) and with a decrease in the number and
size of PSD-95-positive clusters in the stratum radiatum of the CA1. Moreover, these
alterations in structural synaptic plasticity were associated with a strong reduction of
neuronal NF-κB in the pyramidal layer of the CA1 in He−/− mice. Altogether, our data
indicate that alterations involving the molecular axis Helios-WDFY1 in neurons during
the development of core brain regions could be relevant for the pathophysiology of
neuropsychiatric disorders such as schizophrenia.
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INTRODUCTION
Schizophrenia is a chronic debilitating neuropsychiatric disorder
affecting approximately 1% of the population worldwide
(Saha et al., 2005). Symptoms cluster into three categories:
positive (hallucinations, delusions, and agitation), negative
(social withdrawal, anhedonia, and poverty of thought), and
cognitive (working memory and social cognition deficits)
(Kahn et al., 2015). The onset of the disease occurs typically
around post-adolescence (Kahn et al., 2015), and it is considered
to be a multifactorial neurodevelopmental disorder (van Os
et al., 2010). Immunopathogenesis has been proposed as a
possible cause of schizophrenia. According to this hypothesis,
the aberrant interaction of the immune system with the
central nervous system may provoke alterations such as
brain inflammation contributing to schizophrenia (Corsi-
Zuelli et al., 2017). In support of the immunopathogenesis
theory, early infections and other immune alterations during
pregnancy and early post-natal life have been shown to
contribute to schizophrenia (Cordeiro et al., 2015). Therefore,
genetic predisposition together with both immunological
and neural alterations during development could trigger
schizophrenic symptoms.
The Ikaros family of transcription factors is required for the
normal development of lymphocytes and other blood cell lineages
and to produce cytokines (Merkenschlager, 2010). This family
is comprised of five related factors (Ikaros, Helios, Aiolos, Eos,
and Pegasus, or IKZF1-5, respectively), which are expressed at
different times during B and T cell development (Thornton et al.,
2010; Mitchell et al., 2017). Interestingly, we and others have
shown that, only during development, Helios is also present in
neuronal cell subtypes in the striatum and hippocampus (Martín-
Ibáñez et al., 2012, 2017), which are key affected brain regions in
schizophrenia patients (Silbersweig et al., 1995; Yoon et al., 2013).
Using a high throughput RNAseq approach, we have identified a
core Helios target, the Wdfy1 (WD Repeat and FYVE Domain
Containing 1) gene, which is aberrantly upregulated in the
hippocampus and striatum of mice devoid of Helios (Giralt et al.,
2019). The WDFY1 protein is an adaptor protein for the Toll-
like receptor 3 and 4 (TLR3/4) signaling pathway and it mediates
the innate and adaptative immune responses by recruiting the
TIR-domain-containing adaptor (TRIF). Therefore, it could play
a role by promoting the innate immunity pathway in neurons
by activating molecules such as nuclear factor kappa B (NF-κB)
(Hu et al., 2015). Interestingly, TLR3 has been shown to regulate
the expression of DISC1 (from Disrupted in schizophrenia 1)
in neurons (Chen et al., 2017), directly linking this signaling
pathway to schizophrenia.
In the present work we show that aberrantly and sustained
upregulated levels of the Wdfy1 gene are a very specific
and long-lasting molecular hallmark in mice devoid of Helios
(He−/− mice) in different brain regions. At cellular level, this
increase was localized in apical and basal dendrites of the
CA1 pyramidal neurons. Interestingly, He−/− mice showed
several schizophrenia-like phenotypes. In this line, WDFY1
protein levels were aberrantly upregulated in several brain
regions of human post-mortem samples from patients with




For in vivo experiments in adult mice (all in a C57BL/6 strain
background), we used mice devoid of IKZF2 (He−/−, MGI Cat#
4355175, RRID:MGI:4355175), which is the gene that encodes for
the Helios protein. Briefly, Helios-deficient mice were generated
by using a targeting vector and recombination strategy where
the C-terminal part of Helios exon 7 was replaced by a 1.8
kb floxed PGK-neo-poly(A) cassette between the SalI and XbaI
sites (Cai et al., 2009). The full knockout mice (He−/−) were
previously verified (Giralt et al., 2019) and obtained from crosses
between heterozygous mice (He± × He±). Mouse genotyping
was performed by polymerase chain reaction (PCR) in tail biopsy
samples as described elsewhere (Cai et al., 2009). Mice were
housed with access to food and water ad libitum in a colony room
kept at 19–22◦C and 40–60% humidity, under a 12:12 h light/dark
cycle. For experiments in “adult” mice, we used 8-week-old males
and females (the exact number from each gender is specified
in each figure legend) to make their age comparable to the
age of schizophrenia onset in humans (adolescence/youth) and
because younger mice trend toward behaving in an unpredictable
ways (from our records). For the developmental experiments
the age is specified in each figure legend. Experimental animals
were used in accordance with the ethical guidelines (Declaration
of Helsinki and NIH, publication no. 85–23, revised 1985,
European Community Guidelines, and approved by the local
ethical committee (University of Barcelona, C-136/19).
Homing Test
Animals were separated from the dam and kept for 30 min in
the small electric mat at 28 ± 1◦C. Individual pups were then
transferred to a Plexiglas arena (40× 30× 10 cm), with the floor
subdivided by 2.5 × 2.5 cm squares. Wood shavings from the
home cage were evenly spread under the wire mesh floor on one
side of the arena (20× 15 cm, goal arena) and the pup was placed
close to the wall on the opposite side. The time required for each
pup to place both forelimbs within the goal area was recorded
(cut-off time 3 min). This behavior was monitored at postnatal
days 10 and 14 (P10 and P14).
Three Chamber Sociability Test
The apparatus consisted of three interconnected lined
compartments with open doors. Subject mice were habituated
to the central compartment with closed doors for 5 min. After
the habituation phase, the doors were removed and subjects
were tested in the sociability task, and 10 min later the social
memory task was performed to evaluate preference for social
novelty for 10 additional minutes. Thus, the sociability task
consisted of placing the subject mice in the middle chamber
and allowing them to explore for 5 min. The doorways into the
two side chambers were obstructed by plastic boxes during this
habituation phase. After the habituation period, the plastic boxes
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were removed and an unfamiliar mouse (stranger 1) was placed
in one of the side chambers enclosed in a small, round wire
cage that allowed nose contact between the bars but prevented
fighting. In the social memory task, a second, unfamiliar mouse
was placed in the chamber that had been empty during the
first 10 min session (or sociability task). This second stranger
(stranger 2) was also enclosed in an identical small wire cage. The
test mouse had a choice between the first, already-investigated
unfamiliar mouse (stranger 1) and the novel unfamiliar mouse
(stranger 2). Time sniffing/exploring each small cage were
measured using the SMART junior software (Panlab).
Impulsivity/Jumping Test
The jumping behavior was evaluated with the use of a round
platform (an inverted glass container with a diameter of
13 cm and a height of 20 cm); mice were placed on the top
of the platform, and their behavior was video recorded for
15 min. Latency to jump out of the platform was measured
(Matsuoka et al., 2005).
Amphetamine and Apomorphine
Treatments
Locomotor activity was measured in an open field and recorded
with a video caption system. Animals were placed into the
center of an open field arena (a white square arena measuring
40 × 40 × 40 cm in length, width, and height respectively),
and left to habituate for 25 min. Dim light intensity was 60
lux throughout the arena. After this period, mice received
an intraperitoneal injection of vehicle (0.9% NaCl), R-(-)-
apomorphine (0.5 mg/kg; SIGMA A4393), or D-amphetamine
sulfate (3 mg/kg; TOCRIS 2813) as previously described (Pineda
et al., 2005; Sherrill et al., 2013) and their behavior was recorded
over the following 45 min. The same mice were evaluated with
both dopaminergic stimulants. Data caption were recorded at
1 min intervals using the SMART Junior Software (Panlab) and
the distance covered/pathlength (in cm) was analyzed.
Tissue Fixation and Immunofluorescence
Mice were euthanized by cervical dislocation. Left hemispheres
were removed and fixed for 72 h in paraformaldehyde solution
(4% in a phosphate buffer 0.1M). 40 µm coronal sections
were obtained using a Leica Vibratome (Leica VT1000S). Next,
free-floating sections were washed three times in PBS, treated
with NHCl for 30 min, and washed again three times with
PBS. Floating sections were permeabilized in PBST (0.3%) with
0.02% Azide, 2% BSA, and 3% NGS (Ab buffer) for 1 h at
room temperature. After three washes in PBS, brain slices
were incubated overnight at 4◦C with WDFY1 rabbit 1:100
(Bioss Abs, bs-13169R) or with NF-κB rabbit 1:200 (Santa
Cruz Biotechnology Cat# sc-372, RRID:AB_632037). Sections
were then washed three times and incubated for 2 h at room
temperature with fluorescent secondary antibody AlexaFluor 488
goat anti-rabbit (1:400; from Jackson ImmunoResearch, West
Grove, PA, United States). Immunofluorescence specificity was
confirmed in slices without primary antibody. Sections were
analyzed using a two-photon confocal microscope (Leica SP5).
DioListic Staining and Spine Counting
Striatal neurons were labeled using the Helios Gene Gun System
(Bio-Rad) as previously described (Brito et al., 2014). Briefly, a
suspension buffer containing 3 mg of DiI (Molecular Probes,
Invitrogen) dissolved in 100 µl of methylene chloride (Sigma-
Aldrich) and mixed with 50 mg of tungsten particles (1.7 mm
diameter; Bio-Rad) was spread on a glass slide and air-dried. The
mixture was resuspended in 3.5 ml distilled water and sonicated.
Subsequently, the mixture was drawn into Tefzel tubing (Bio-
Rad), and then removed to allow tube drying during 5 min under
a nitrogen flow gas. The tube was then cut into 13 mm pieces
to be used as gene gun cartridges. Dye-coated particles were
delivered in the striatum using the following protocol: shooting
was performed over 200 µm coronal sections at 80 psi through
a membrane filter of 3 µm pore size and 8 × 10 pores/cm2
(Millipore). Sections were stored at room temperature in PBS
for 3 h protected from light and then incubated with DAPI
and mounted in Mowiol to be analyzed. DiI-labeled medium-
spiny neurons from striatum were imaged using a Leica Confocal
SP5 with a × 63 oil-immersion objective (digital zoom 5x).
Spine density and morphology analysis was performed using
the freeware Neuronstudio (Computational Neurobiology and
Imaging Center, Icahn School of Medicine at Mount Sinai) as
previously described (de Pins et al., 2019).
Quantitative (Q)-PCR Assay
Total RNA from hippocampus and striatum in He+/+ and
He−/− mice at 8 weeks of age was extracted using the Total RNA
Isolation Nucleospin R© RNA II Kit (Macherey-Nagel, Düren,
Germany). Total RNA (500 ng) was used to synthesize cDNA
using random primers with the StrataScript R© First Strand cDNA
Synthesis System (Stratagene, La Jolla, CA, United States).
The cDNA synthesis was performed at 42◦C for 60 min in a
final volume of 20 µl according to manufacturer’s instructions.
The cDNA was then analyzed by Q-PCR using the following
TaqMan R© Gene Expression Assays (Applied Biosystems,
Foster City, CA, United States): 18S (Hs99999901_s1),
Ngfr (Mm00446294_m1), and Vsnl1 (Hs00374305_m1); or
Integrated DNA Technologies (IDT): Adcy8 (NM_009623), Aif1
(NM_019467), Grm2 (NM_001160353), Kcne4 (NM_021342),
Lancl1 (NM_001190984 and NM_021295), Pth2r (NM_139270),
and Wdfy1 (NM_001111279 and NM_001111279). Reverse-
transcriptase (RT) polymerase chain reaction was performed in
25 µl volumes on 96-well plates, in a reaction buffer containing
12.5 µl Brilliant R© Q-PCR Master Mix (Stratagene), 1.25 µl
TaqMan R© Gene Expression Assays, and 10–20 ng of cDNA.
Reactions were as follows: 40 cycles of a two-step PCR; 95◦C
for 30 s and 60◦C for 1 min, after initial denaturation at 95◦C
for 10 min. All RT-PCR assays were performed in duplicate
and repeated for at least three independent experiments.
To provide negative controls and exclude contamination by
genomic DNA, the RT was omitted in the cDNA synthesis
step, and the samples were subjected to the PCR reaction in
the same manner with each TaqMan R© Gene Expression Assay.
The RT-PCR data were analyzed using the MxProTM Q-PCR
analysis software version 3.0 (Stratagene). Quantification was
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performed with the Comparative Quantitation Analysis program
of the mentioned software and using the 18S gene expression as
internal loading control.
Pharmacological Treatments
C57BL/6 male mice (10 weeks old) were injected intraperitoneally
with D-amphetamine (3 mg/kg) or with a sub-anesthetic dose
of ketamine (30 mg/kg) for 8 days once per day as previously
described (Manning et al., 2016; McDougall et al., 2017). On
day 8, mice were sacrificed 15 min after injection and the
hippocampus, and the striatum were rapidly dissected out and
frozen at −80◦C for future use in western blot experiments
(see western blot section). Another group of C57BL/6 male mice
at postnatal day 5 were injected intraperitoneally with vehicle
or lipopolysaccharides (LPS, 6 mg/kg; Cardoso et al., 2015)
or polyinosinic:polycytidylic acid (Poly I:C, 6 mg/kg; Baghel
et al., 2018). 24 h later, mice were sacrificed by decapitation
and the hippocampus, striatum, and frontal cortex were rapidly
dissected out and frozen at −80◦C for future use in western blot
experiments (see western blot section).
Human Post-mortem Samples
The brain samples from schizophrenia (SZ) patients used in
this study were provided by the Sant Joan de Déu Brain Bank
(Sant Boi de Llobregat, Barcelona, Spain). The donation and
obtaining of samples were regulated by the ethics committee of
both institutions. The sample processing followed the rules of the
European Consortium of Nervous Tissues: BrainNet Europe II
(BNEII). All the samples were protected in terms of individual
donor identification following the BNEII laws. Clinical diagnosis
of SZ in donor subjects was confirmed premortem with DMS-
IV (Diagnostic and Statistical Manual of Mental Disorders –
4th edition) and ICD-10 (International Statistical Classification
of Diseases and Related Health Problems) criteria by clinical
examiners. Most donors were hospitalized for more than 40 years
and were re-evaluated every 2 years to monitor and update
their clinical progression. Case information can be found in
Table 1. Post-mortem samples from humans with Alzheimer’s
disease (hippocampus) and controls (hippocampus, putamen,
and dorsolateral prefrontal cortex) were obtained from Banc
de Teixits Neurològics (Servei Científico-Tècnics, Universitat
de Barcelona, Barcelona, Spain) and the sample processing
also followed the BNEII rules. Case information can be found
in Table 2. To distinguish between Alzheimer’s patients with
psychotic symptoms from those without psychotic symptoms,
the NIA-AA clinical criteria was used in patients considering
the patients score in delusions and/or hallucinations of NPI-
Q gravity ≥ 2 (rank from 0 to 3). All the procedures for the
obtention of post-mortem samples followed the ethical guidelines
of the Declaration of Helsinki and local ethical committees
(Universitat de Barcelona: IRB00003099; Fundació CEIC Sant
Joan de Déu: BTN-PSSJD).
Western Blot
Animals were euthanized by cervical dislocation. The
hippocampus was dissected out, frozen using CO2 pellets,
and stored at −80◦C until use. Briefly, the tissue was lysed by
sonication in 150 ml of lysis buffer (PBS, 10 ml l1 Non-idet
P-40, 1 mM PMSF, 10 mg l1 aprotinin, 1 mg l1 leupeptin
and 2 mg l1 sodium orthovanadate). After lysis, samples were
centrifuged at 12,000 r.p.m. for 15 min. Supernatant proteins
(15 mg) from total brain regions extracts were loaded in
polyacrylamide gels (SDS–PAGE) at different polyacrylamide
concentrations and transferred to nitrocellulose membranes
during 1 h. Membranes were blocked in TBS-T (150 mM NaCl,
20 mM Tris-HCl, pH 7.5, 0.5% Tween 20) with 5% non-fat dry
milk and 5% BSA. Immunoblots were probed with the following
antibodies: anti-WDFY1 rabbit 1:1000 [SIGMA, # HPA050603;
RRID:AB_2681188 (specific for humans)], anti-WDFY1 rabbit
1:1000 [Bioss Abs, bs-13169R (for mice)], anti-VSNL1 rabbit
1:1000 (Proteintech, 13919-1-AP; RRID:AB_2215851), and
anti-DISC1 (Proteintech Cat# 15500-1-AP, RRID:AB_2230451).
All blots were incubated with the primary antibodies overnight
at 4◦C by shaking in PBS with 0.2 g l-1 sodium azide. After
several washes in TBS-T, blots were incubated with anti-rabbit
or anti-mouse horseradish-peroxidase-conjugated secondary
antibodies (1:2000; Promega). Secondary antibody binding was
detected by the enhanced chemiluminescence substrate kit (Santa
Cruz Biotechnology). For loading control, a mouse monoclonal
antibody for α-tubulin was used (#083M4847V, 1:30,000; Sigma).
ImageJ software was used to quantify the different densitometry
immunoreactive bands relative to the intensity of the α-tubulin
in the same membranes.
Statistical Analysis
All data are expressed as mean ± SEM. Statistical analysis were
performed using the unpaired two-sided Student’s t-test (95%
confidence), one-way ANOVA with the Tukey’s as post hoc
tests, and two-way ANOVA with the Bonferroni’s post hoc
test as appropriate and indicated in the figure legends. Values
of p < 0.05 were considered as statistically significant. All
experiments in this study were blinded and randomized. All mice
bred for the experiments were used for pre-planned experiments
and randomized to experimental groups. Data were collected,
processed and analyzed randomly. The experimental design and
handling of mice were identical across experiments. Littermates
were used as controls with multiple litters (three to five) examined
per experiments.
RESULTS
Wdfy1 Is the Only Differentially
Expressed Gene That Remains
Up-Regulated in the Hippocampus and
Striatum of Adult He−/− Mice
In a previous study, we carried out a RNAseq experiment at
embryonic day 18 (E18) and we identified some genes that
were differentially expressed in He−/− mice compared to He+/+
mice in both the striatum and the hippocampus (Giralt et al.,
2019). Thereby, here we first aimed to verify whether these
previously identified genes and others were still dysregulated in
the hippocampus and in the striatum of 8-week-old He−/− mice
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TABLE 1 | Demographics, treatments, and illness details for human post-mortem samples from patients with schizophrenia and controls.
Case ID Diagnostic Gender Age (years) PMI (h) Medication
1557 Control M 86 7 NA
1679 Control F 90 14 NA
1694 Control M 58 5 NA
1752 Control F 88 24 NA
1818 Control M 78 5 NA
1858 Control F 83 7 NA
1870 Control F 97 7 NA
1888 Control F 93 6 NA
1937 Control F 83 8 NA
1949 Control M 86 8 NA
0810 Control F 81 23 NA
1074 Control M 31 17 NA
0364 Control F 68 13 NA
0034 Control M 64 4 NA
0839 Control M 56 4 NA
0162 Control F 71 8 NA
0024 Control F 60 15 NA
0044 Control M 39 4 NA
1491 Control M 83 13 NA
1563 Control M 79 5 NA
1570 Control F 86 4 NA
1697 Control M 78 6 NA
1733 Control M 76 11 NA
1774 Control F 74 5 NA
P_001 Chronic residual schizophrenia M 34 2 NA
P_003 Chronic residual schizophrenia M 80 6 NA
P_008 Chronic residual schizophrenia M 74 7 Levomepromazine 75 mg/day Haloperidol 15 mg/day
P_011 Chronic residual schizophrenia M 76 7 Quetiapine 250 mg/day
P_017 Chronic paranoid schizophrenia M 69 8 Quetiapine 500 mg/day
P_019 Chronic residual schizophrenia M 79 3 Levomepromazine 13 mg/day, Quetiapine 600 mg/day
P_020 Chronic residual schizophrenia M 65 4 Quetiapine 1000 mg/day, Amisulpride 800 mg/day
P_021 Schizoaffective disorder M 82 4 Haloperidol 15 mg/day, Olanzapine 20 mg/day
P_022 Chronic residual schizophrenia M 79 9 Perphenazine 40 mg/day, Thioridazine 100 mg/day, Sulpiride
200 mg/day, Haloperidol: 10 mg/day
P_025 Chronic residual schizophrenia M 98 8 NA
P_026 Chronic residual schizophrenia M 77 6 Olanzapine 20 mg/day
P_027 Chronic residual schizophrenia M 84 3 Olanzapine 15 mg/day
P_028 Chronic residual schizophrenia M 79 3 NA
P_029 Chronic residual schizophrenia M 80 5 Olanzapine 15 mg/day
P_032 Chronic residual schizophrenia M 92 2 Quetiapine 100 mg/day
P_033 Chronic residual schizophrenia M 87 4 Olanzapine 5 mg/day
P_034 Chronic residual schizophrenia M 93 3 NA
P_035 Chronic schizophrenia. Paranoid type M 86 1 Levomepromazine 5 mg/day
P_037 Chronic residual schizophrenia M 74 9 Levomepromazine 50 mg/day, Olanzapine 10 mg/day
P_038 Chronic residual schizophrenia M 75 6 Olanzapine 10 mg/day
P_041 Delusional disorder – Erotomaniac type F 81 5 NA
P_042 Chronic residual schizophrenia M 77 2 Risperidone 2 mg/day, Quetiapine 1000 mg/day
P_044 Chronic disorganized schizophrenia M 78 8 NA
P_045 Chronic residual schizophrenia F 86 2 Haloperidol 15 mg/day
P_046 Chronic residual schizophrenia M 82 6 Risperidone 2 mg/day
P_049 Chronic residual schizophrenia M 79 7 Haloperidol 3 mg/day
P_052 Chronic residual schizophrenia M 81 6 NA
P_053 Schizophrenia. Paranoid type. In remission M 80 2 NA
(Continued)
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TABLE 1 | Continued
Case ID Diagnostic Gender Age (years) PMI (h) Medication
P_055 Chronic residual schizophrenia M 76 5 Sulpiride 200 mg/day
P_056 Chronic residual schizophrenia M 83 4 Quetiapine 50 mg/day
P_058 Chronic residual schizophrenia M 87 9 NA
P_059 Chronic residual schizophrenia M 83 4 Chlorpromazine 200 mg/day, Haloperidol 10 mg/day, Olanzapine
20 mg/day, Levomepromazine 100 mg/day, Perphenazine
30 mg/day, Tioproperazine 20 mg/day,
P_062 Chronic residual schizophrenia M 81 8 NA
P_064 Chronic residual schizophrenia M 89 1 NA
P_065 Chronic residual schizophrenia M 76 8 Perphenazine 4 mg/day, Olanzapine 5 mg/day
P_068 Chronic residual schizophrenia M 90 3 NA
P_069 Chronic residual schizophrenia M 86 6 NA
P_072 Chronic residual schizophrenia M 83 6 NA
P_074 Chronic residual schizophrenia M 85 2 Haloperidol 2 mg/day
P_076 Chronic residual schizophrenia M 75 6 Levomepromazine 25 mg/day, Olanzapine 10 mg/day
P_077 Chronic disorganized schizophrenia M 84 3 Amisulpride 200 mg/day
P_080 Chronic residual schizophrenia M 81 2 Zyprexa 10 mg/day, Haloperidol 3 mg/day; Olanzapine 5 mg/day,
Tioridazine 150 mg/day,
P_084 Chronic schizophrenia. Catatonic type M 71 8 Quetiapine 300 mg/day, Olanzapine 40 mg/day
P_086 Chronic schizophrenia. Catatonic type M 82 7 NA
P_087 Chronic residual schizophrenia M 74 4 Quetiapine 350 mg/day, Haloperidol 5 mg/day,
P_089 Chronic residual schizophrenia M 67 7 Olanzapine 10 mg/day, Quetiapine 75 mg/day, Haloperidol
20 mg/day
P_091 Chronic residual schizophrenia a M 91 3 NA
P_092 Chronic residual schizophrenia M 78 6 Haloperidol 1 mg/day
P_093 Chronic residual schizophrenia M 69 7 Haloperidol 15 mg/day, Risperidone 12 mg/day, Olanzapine
30 mg/day
P_096 Schizophrenia. Simple type M 58 2 Haloperidol 15 mg/day
P_097 Chronic residual schizophrenia M 50 2 Haloperidol 15 mg/day
P_100 Chronic residual schizophrenia M 69 3 NA
P_102 Chronic schizophrenia. Paranoid type M 64 3 Olanzapine 20 mg/day
PMI, Post-mortem interval; M, Male; F, Female; NA, Not applicable.
compared to age-matched He+/+ mice. All the genes identified
to be altered at E18 – Kcne4, Lancl1 (two different probes:
exon 1c-2 and exon 7–9), Pth2r, and Vsnl1 – were similarly
expressed in 8-week-old He−/− mice compared to He+/+ litters
in the striatum (Figure 1A) as well as in the hippocampus
(Figure 1B). Surprisingly, Wdfy1 was the only gene that remained
up-regulated in 8-week-old He−/− mice compared to controls in
both brain regions, striatum (Figure 1A; t10 = 7.54, p < 0.001)
and hippocampus (Figure 1B; t10 = 7.163, p < 0.001). Gene
expression of Wdfy1 was further confirmed by using two different
probes (exon 3–5 and exon 6–7). We then evaluated the mRNA
levels for additional genes. Furthermore, we analyzed the mRNA
levels of the Aif1 gene since it is a very well-known marker of
immune activation (macrophage and t-cell activation) (Kelemen
and Autieri, 2005). The Grm2 gene encodes for the mGuR2
receptor, which is a marker of macrophage inflammatory protein
1b and also a crucial regulator of hippocampal synaptic plasticity
(Betke et al., 2012), a process that is severely affected in He−/−
mice (Giralt et al., 2019). Adcy8 was used as a marker of the
CA1 hippocampal subregion (de Mooij-van Malsen et al., 2009)
where the Helios protein was enriched during development
(Martín-Ibáñez et al., 2012). In summary, all of these genes
were not different between 8-week-old He−/− mice compared
to age-matched He+/+ mice. Finally, we further validated this
genetic Wdfy1 up-regulation in the CA1 of adult He−/− mice
by immunofluorescence (Figure 1C). By using this approach,
we observed a significant increase on Wdfy1 protein levels in
He−/− mice. This was mostly localized in the stratum radiatum
[Two-way ANOVA, group effect: F(1,182) = 106.9, p < 0.0001]
and in the stratum oriens [Two-way ANOVA, group effect:
F(1,252) = 26.11, p < 0.0001], but also in the stratum pyramidale to
a lesser extent [Two-way ANOVA, group effect: F(1,216) = 5.203,
p < 0.0105], indicating that, probably, such upregulation was
mostly localized in the apical and basal dendrites of the CA1
pyramidal neurons.
The WDFY1 Protein Is Upregulated in
Different Brain Regions of Schizophrenic
Patients but Not in Alzheimer’s Disease
Patients
As far as we know, the function of the WDFY1 protein
in the central nervous system is practically unknown. It
has been reported that WDFY1 could be a biomarker
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TABLE 2 | Demographics and illness details for human post-mortem hippocampal samples from patients with Alzheimer’s disease and controls.
Case ID Diagnostic Gender Age (years) PMI (h) Medication
1557 Control M 86 7 NA
1679 Control F 90 13 NA
1694 Control M 58 5 NA
1752 Control F 88 24 NA
1818 Control M 78 5 NA
1870 Control F 97 7 NA
1888 Control F 93 5 NA
1949 Control M 86 7 NA
1127 Alzheimer’s, no psychosis M 82 8 NA
1785 Alzheimer’s (early onset), no psychosis F 74 4 NA
1800 Alzheimer’s, no psychosis M 84 5 NA
1803 Alzheimer’s (cortico-basal dementia), no psychosis M 72 18 NA
1822 Alzheimer’s, no psychosis F 82 6 NA
1824 Alzheimer’s, no psychosis F 84 6 NA
1829 Alzheimer’s, no psychosis M 83 5 NA
1847 Alzheimer’s, no psychosis F 75 16 NA
1879 Alzheimer’s (early onset), no psychosis F 63 10 NA
1882 Alzheimer’s (early onset), no psychosis M 72 5 NA
1037 Alzheimer’s (early onset) with psychosis M 56 16 NA
1273 Alzheimer’s (early onset) with psychosis M 61 8 NA
1321 Alzheimer’s (early onset) with psychosis M 63 8 NA
1380 Alzheimer’s with psychosis F 85 10 NA
1386 Alzheimer’s with psychosis M 81 3 NA
1443 Alzheimer’s (early onset) with psychosis F 63 6 NA
1444 Alzheimer’s (early onset) with psychosis M 62 20 NA
1457 Alzheimer’s with psychosis F 76 13 NA
1614 Alzheimer’s with psychosis F 85 12 NA
1736 Alzheimer’s with psychosis F 86 8 NA
PMI, Post-mortem interval; M, Male; F, Female; NA, Not applicable.
for the phenotype severity in the AD11 mouse model
of Alzheimer’s disease (Arisi et al., 2011). Additionally,
WDFY1 could play a role on TLR3/4 signaling during the
differentiation of adult neural stem cells in the dentate
gyrus (Yeo et al., 2019). Despite this poor information
about the role of WDFY1 in the central nervous system, a
previous report where the authors performed a transcriptome
outlier analysis placed WDFY1 as a putative upregulated
marker in schizophrenia (Duan et al., 2015). Furthermore,
in another report the authors showed that WDFY1 could be
associated with the DISC1 (from disrupted in schizophrenia 1)
interactome and regulome (Teng et al., 2018). Thereby we
next aimed to verify whether WDFY1 was dysregulated in
post-mortem samples from patients with schizophrenia (see
Table 1 for sample information). First, we evaluated WDFY1
protein levels in the hippocampal samples and we found
that WDFY1 was significantly upregulated (t46 = 2.845,
p = 0.0065) in patients with schizophrenia compared to
controls (Figure 2A). These changes did not depend on age
(Figure 2B) or post-mortem time intervals (Figure 2C). In
the case of dorsolateral prefrontal cortex, we also observed a
significant upregulation of WDFY1 protein levels (t46 = 2.018,
p = 0.049) in schizophrenic patients compared to controls
(Figure 2D). Again, these changes did not depend on age
(Figure 2E) or post-mortem time intervals (Figure 2F). In
contrast, although we observed a trend, WDFY1 protein
levels were not significantly upregulated in the putamen of
schizophrenic patients compared to controls (Figure 2G).
Next, to verify the specificity of these changes, we also
evaluated the VSNL1 protein levels in the same hippocampal
samples as we did for He−/− mice. Interestingly, VSNL1
protein levels were unchanged in schizophrenic patients
compared to controls (Figure 2H). The latter result correlates
well with that observed in adult He−/− mice compared
with He+/+ mice (Figures 1A,B). Finally, since WDFY1
could serve as a biomarker in Alzheimer’s disease (AD),
we evaluated WDFY1 protein levels in the hippocampus
of AD patients (see Table 2 for sample information) with
(AD+) or without (AD-) psychosis compared to controls
(Figure 2I). No changes were observed in any subgroup of AD
patients compared to controls indicating a possible specificity
of this WDFY1 upregulation in patients with schizophrenia
but not in patients with AD and psychosis. However, a
limitation of the experiment with AD samples was the high
variability between samples making its interpretation still a
bit inconclusive.
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FIGURE 1 | WDFY1 protein and gene expression in He−/− mice. (A) mRNA levels of Adcy8, Aif1, Grm2, Kcne4, Lancl1 (two different probes: exons 1c-2 and exons
7–9), Ngfr, Pth2r, Vsnl1, and Wdfy1 (two different probes: exons 3–5 and exons 6–7) were determined in striatal samples of 8-week-old He+/+ and He−/− mice
(n = 6 He+/+ and 6 He−/−; 3 males and 3 females per genotype). (B) mRNA levels of Adcy8, Aif1, Grm2, Kcne4, Lancl1 (two different probes: exons 1c-2 and
exons 7–9), Ngfr, Pth2r, Vsnl1, and Wdfy1 (two different probes: exons 3–5 and exons 6–7) were determined in hippocampal samples of 8-week-old He+/+ and
He−/− mice (n = 6/genotype). (C) Double staining for DAPI (blue) and WDFY1 (green) in the hippocampal CA1 of 8-week-old He+/+ and He−/− mice (left). White
squares represent inset zones with their magnifications placed at right of each original CA1 image. Quantification (n = 2 He+/+ males and 2 He+/+ females, and 2
He−/− males and 3 He−/− females) of the intensity of the optical density (IOD) in the CA1 is shown separately for stratum oriens (S.O.), stratum pyramidale (S.P.),
and stratum radiatum (S.R.). A linear intensity profile analysis as a mean IOD was performed in each image. Points in the X axis indicate mean IOD for each row of
pixels. An independent statistical analysis was performed in each CA1 layer. Bars represent mean ± SEM. Data were analyzed by Student’s t-test for each gene in
(A,B) and by two-way analysis of variance (ANOVA) in (C). In (A), ***p = 0.000106 and p = 0.0008 for Wdfy1 ex.3–5 and Wdfy1 ex.6–7 respectively when compared
with He+/+ mice. In (B), ***p = 1,971446e-005 and p = 0.00018 for Wdfy1 ex.3–5 and Wdfy1 ex.6–7 respectively when compared with He+/+ mice. Scale bar, 70
(left images) and 10 µm (right images).
He−/− Mice Display Altered Impulsive
and Dopamine-Associated Behaviors
Related to Striatal Dysfunction
Since WDFY1 is up-regulated in the striatum and hippocampus
of He−/− mice and in different brain regions of patients
with schizophrenia, we then sought to characterize whether
He−/− mice would recapitulate some of the schizophrenia-
like phenotypes. To deepen on striatal deficiencies related
to schizophrenia-like phenotypes, we subjected the 8-week-
old He+/+ and He−/− mice to the impulsivity test and to
treatments with the dopaminergic agonists called amphetamine
and apomorphine. First, we noticed that He−/− mice displayed
a lower body weight during the entire postnatal development
(Figure 3A), which was kept until postnatal day 28 [two-way
ANOVA, group effect: F(1,137) = 477, p < 0.0001] as previously
described (Cai et al., 2009). Next, we measured impulsivity-
like behavior by using the jumping test. In this test, He−/−
mice displayed shorter latencies to jump out from the cylinder
than He+/+ mice (t13 = 3.297, p = 0.0058) suggesting higher
levels of impulsivity (Figure 3B). We then intended to observe
whether He−/− mice suffer agitation-like behaviors or higher
sensitivity to dopaminergic agents. Basal exploratory activity
during the first 25 min of free deambulation in the open
field was not different between genotypes (Figures 3C,F). As
expected, injections with amphetamine- (Figures 3C–E) or with
apomorphine-induced (Figures 3F–H) increases in locomotor
activity in He+/+ (Figure 3D: t10 = 3.094, p = 0.0057, and G:
t7 = 2.045, p = 0.0401) and He−/− (Figure 3G: t10 = 6.522,
p < 0.001, and H: t7 = 2.106, p = 0.0366) mice. However, the
amphetamine- (Figure 3C) but not the apomorphine-induced
(Figure 3F) locomotor activity was more pronounced in He−/−
mice than in He+/+ mice [Two-way ANOVA, group effect after
amphetamine injection: F(59,1175) = 11.67, p < 0.001]. We also
evaluated microstructural changes in the striatum of 8-week-old
He−/− and He+/+ mice by analyzing spine density (Figures 3I–
K) and morphology (Figure 3L) in medium spiny neurons
(MSNs). We found that spine density in MSNs was significantly
increased (t43 = 4.969, p < 0.001) in He−/−mice when compared
with He+/+ mice (Figures 3I–K). Regarding spine morphology
(Figure 3L), we detected a clear and specific increase in the
density of thin spines in He−/− compared with He+/+ mice
[Two-way ANOVA, genotype effect: F(1,129):27.52, p < 0.001;
Interaction effect: F(2,129):15.74, p < 0.001]. No changes in the
density of mushroom or stubby spines were detected between
groups (Figure 3L). All results taken together suggest that He−/−
mice display a striatal-related psychiatric phenotype.
He−/− Mice Display Impaired
Socio-Cognitive Behaviors Related to
Hippocampal Dysfunction
We previously observed that He−/− mice show alterations in
spatial learning and memory (Giralt et al., 2019) as occurs
in schizophrenic patients (Venkatasubramanian et al., 2014).
These deficiencies could be strongly related with a hippocampal
dysfunction, a brain region where Helios protein was highly
expressed during development (Martín-Ibáñez et al., 2012). We
then aimed to evaluate other hippocampal-related phenotypes
described to be core symptoms in schizophrenia such as
alterations in social behavior (Martinez et al., 2019). We first
evaluated maturation of social-cognitive function in pups at
early post-natal developmental stages by using the homing
test (Alleva and Calamandrei, 1986; Scattoni et al., 2005). The
results showed that the homing test latency was significantly
lower in He+/+ pups at postnatal day 14 (P14) than at P10,
indicating a maturation and improvement of the socio-cognitive
and neurological functions necessary to solve this task. However,
He−/− pups showed no significant improvements in the homing
test latencies at P14 compared to P10 and consequently, they
showed significantly higher latencies than He+/+ pups at P14
(Figure 4A, t11 = 2.267, p = 0.0445). To further confirm
these social deficiencies, we performed the three-chamber social
interaction test in 8-week-old He−/− and He+/+ mice. In a
first phase, He−/− mice showed normal sociability (Figure 4B).
However, in a second phase He−/−mice showed decreased social
memory and social novelty preference [Two-way ANOVA, group
effect: F(1,20) = 43.75, p < 0.0001] when compared with He+/+
mice (Figure 4C).
We next aimed to explore putative changes in excitatory
synapses associated with spine alterations previously reported in
the pyramidal neurons of the He−/− mice (Giralt et al., 2019).
Such changes could have a potential correlation with their deficits
in social skills. We evaluated the postsynaptic marker called
PSD-95 previously reported to be decreased in the hippocampal
CA1 of schizophrenic patients (Matosin et al., 2016). Thereby,
we analyzed this marker in the CA1 stratum radiatum of
8-week-old He+/+ and He−/− mice. We observed that the
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FIGURE 2 | WDFY1 protein levels in patients with schizophrenia and in patients with Alzheimer’s disease with or without psychosis. (A) Immunoblotting for WDFY1
and Tubulin as a loading control in the hippocampus of human post-mortem samples from patients with schizophrenia (SCH) and control (CNT) individuals (n = 16
CNT and 32 SCH). Correlation analysis comparing WDFY1 protein levels in schizophrenic patients from (A) with (B) age or (C) post-mortem interval (PMI).
(D) Immunoblotting for WDFY1 and Tubulin as a loading control in the dorsolateral prefrontal cortex of human post-mortem samples from patients with schizophrenia
and control individuals (n = 10 CNT and 38 SCH). Correlation analysis comparing WDFY1 protein levels in schizophrenic patients from (D) with (E) age or (F)
post-mortem interval (PMI). (G) Immunoblotting for WDFY1 and Tubulin as a loading control in the putamen of human post-mortem samples from patients with
schizophrenia and control individuals (n = 8 CNT and 53 SCH). (H) Immunoblotting for VSNL1 and Tubulin as a loading control in the hippocampus of human
post-mortem samples from patients with schizophrenia and control individuals (n = 16 CNT and 46 SCH). (I) Immunoblotting for WDFY1 and Tubulin as a loading
control in the hippocampus of human post-mortem samples from patients with Alzheimer’s disease with (AD +) or without (AD-) associated/diagnosed psychotic
symptoms and control (CNT) individuals (n = 8 CNT, 10 AD-, and 10 AD+). Bars represent mean ± SEM. Data were analyzed by Student’s t-test in (A,D,G,H), by
Pearson’s correlation coefficient in (B,C,E,F) and by one-way ANOVA in (I) with the Tukey’s test as a post hoc. *p = 0.049, **p = 0.0065 when compared with CNT.
number of PSD-95-positive puncta was significantly decreased
(t8 = 2.37, p = 0.0453) in He−/− compared with He+/+ mice
(Figures 4D,E). Furthermore, the size of the PSD-95-positive
puncta was also significantly reduced (t8 = 3.768, p = 0.005)
in He−/− mice with respect to He+/+ mice (Figure 4F).
In summary, these results suggest that the social deficiencies
observed in He−/− mice compared with He+/+ mice were
accompanied by changes in the number and size of PSD-95-
positive clusters in the apical dendrites of the CA1.
NF-κB Levels Are Reduced in the
Neuronal Soma of CA1 Pyramidal
Neurons in He−/− Mice
Since WDFY1 increased levels were observed in the hippocampus
of both schizophrenic patients and 8-week-old He−/− mice, we
then evaluated the levels of DISC1 and the distribution of NF-κB
in this brain region. We selected these molecular targets because
DISC1 is a well-known genetic risk factor for schizophrenia
(Porteous et al., 2014) and it has been shown to be a target
of TLR3/4 downstream signaling (Chen et al., 2017). NF-κB
was evaluated because the TLR3/4-dependent regulation of NF-
κB is potentiated when WDFY1 is over-expressed (Hu et al.,
2015) and NF-κB is a core neuroinflammatory molecule involved
in the pathogenesis of schizophrenia (Dwir et al., 2019). First,
we observed that DISC1 protein levels were unchanged in the
striatum and in the hippocampus of 8-week-old He−/− mice
compared to He+/+ litters (Figures 5A–C). Then, we evaluated
by immunofluorescence the levels and distribution of NF-κB
(p65) in the CA1 of He−/− and He+/+ mice (Figure 5D).
Unexpectedly, we found a significantly reduced NF-κB (p65)
expression (t16 = 7.772, p = 0.001), specifically in the pyramidal
cell layer of the dorsal hippocampus in He−/− mice compared
with age-matted He+/+ litters (Figures 5D,E). These results
suggest a connection between the increase on WDFY1 levels and
the reduction of NF-κB in the hippocampus of He−/− mice.
Pharmacological Models of
Schizophrenia Do Not Induce Changes in
WDFY1 Protein Levels
As we have seen increased WDFY1 protein levels in
the hippocampus and striatum of He−/− mice and
in the hippocampus and dorsolateral prefrontal cortex in
schizophrenic post-mortem samples, we then hypothesized
that pharmacological models of schizophrenia could mimic
such molecular changes. First, we treated 10-week-old male
wild-type mice with vehicle or amphetamine (3 mg/kg) or
ketamine (30 mg/kg) for 8 days. All mice were sacrificed
15 min after last injection on day 8. Striatal and hippocampal
samples from these mice were evaluated by western blot to
check for the WDFY1 protein levels. Our results indicate
that WDFY1 protein levels are not influenced by any of both
treatments in any brain region (Figures 6A,B). We then
hypothesized that pharmacological treatments aimed to induce
a strong and persistent neuroinflammatory response during
neurodevelopmental stages could mimic the changes on WDFY1
protein levels as we observed in He−/− mice and human post-
mortem samples from schizophrenic patients. Therefore, we
treated wild-type mouse pups with vehicle or lipopolysaccharides
(LPS, 6 mg/kg) or Poly I:C (6 mg/kg) at postnatal day 5 and
collected striatal, hippocampal, and frontal cortex samples
24 h later. Again, western blot experiments demonstrated
that WDFY1 protein levels are not influenced by any of both
treatments in any brain region analyzed (Figures 6C,D). Taken
together, these results indicate that pharmacological models
of schizophrenia that model dopaminergic- (amphetamine) or
glutamatergic-related (ketamine) pathophysiological events or
neurodevelopmental immunological challenges (LPS or Poly I:C
respectively) do not recapitulate the changes on WDFY1 protein
levels observed in He−/− mice and schizophrenic patients.
DISCUSSION
In the present work we show that mice devoid of Helios (He−/−
mice) recapitulate negative schizophrenic-like symptoms
classically modeled in rodents, namely increased impulsivity,
amphetamine-induced locomotor activity, and decreased social
skills. Here we also report an increased spine density in MSNs
and decreased excitatory PSD-95 positive clusters in pyramidal
neurons of the CA1 in He−/− mice. All these deficiencies
correlate with a sustained and specific increase on WDFY1
mRNA levels in the striatum and hippocampus. We also showed
increased WDFY1 protein levels in the CA1 but not in the
striatum. Further future studies will be necessary to confirm
the WDFY1 protein levels in the striatum with a potential
predicted increase as we observed when mRNA levels were
analyzed. Accordingly, postmortem samples from schizophrenic
patients but not from Alzheimer’s disease patients also display
an increase of WDFY1 protein levels in the hippocampus and
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FIGURE 3 | Characterization of schizophrenia-like phenotypes related to striatal function in He−/− mice. (A) The curve in graph depicts the body weight gain in both
genotypes, He−/− and He+/+ mice from embryonic day 14.5 (E14.5) to postnatal day 28 (P28) (n = 3 He+/+ males and 4 He+/+ females, and 4 He−/− males and
4 He−/− females). (B) Time to jump out from the glass cylinder in 8-week-old He−/− and He+/+ mice (n = 4 He+/+ males and 4 He+/+ females, and 3 He−/−
males and 4 He−/− females). (C) Locomotor activity in the open field was monitored for 25 min in He−/− and He+/+ mice (n = 6 He+/+ males and 5 He+/+
females, and 5 He−/− males and 6 He−/− females). After these 25 min, all mice received an injection of D-amphetamine sulfate (3 mg/kg) as indicated by the top
arrow in the graph and the locomotor activity was subsequently monitored for additional 45 min. The induced locomotor activation in He+/+ (D) and He−/− (E) mice
was evaluated by comparing representative covered distances from baseline and from treatment as depicted in gray in (C). (F) Locomotor activity in the open field
was monitored for 25 min in He−/− and He+/+ mice (n = 8 He+/+ and 8 He−/−; 4 males an 4 females per genotype). After these 25 min, all mice received an
injection of R-(-)-apomorphine (0.5 mg/kg) as indicated by the top arrow in the graph and the locomotor activity was subsequently monitored for additional 45 min.
The induced locomotor activation in He+/+ (G) and He−/− (H) mice was evaluated by comparing representative covered distances from baseline and from
treatment as depicted in gray in (F). (I) Representative images of a DiI-labeled medium spiny neuron (scale bar = 20 microns) and (J) representative medium spiny
neuron dendrites from 8-weeks-old He+/+ and He−/− mice (scale bar = 3 microns). (K) Quantitative analysis showing dendritic spine density per micron of dendritic
length from 8-week-old He+/+ and He−/− mice (n = 26 dendrites from 5 He+/+ mice, 2 males and 3 females, and 20 dendrites from 5 He−/− mice, 3 males and 2
females). (L) Density of each type of dendritic spine (stubby, thin, and mushroom) in dendrites of medium spiny neurons from (K) in He−/− and He+/+ mice. Total
evaluated spines: 977 from He+/+ mice and 1088 from He−/− mice. Bars represent mean ± SEM. Data were analyzed by unpaired Student’s t-test in (B,K), by
paired Student’s t-test in (D,E,G,H) and by two-way ANOVA in (A,C,F,L). **p < 0.01, ***p < 0.001 when compared with He+/+ mice in (A–C,F,K,L). *p < 0.05,
**p < 0.01 when compared with baseline data in (D,E,G,H).
in the dorso-lateral prefrontal cortex, whereas in He−/− mice
we found an increase of WDFY1 in the hippocampus and
striatum. Therefore, the hippocampus is the only brain region
that commonly displayed increased WDFY1 levels in both,
schizophrenic patients and He−/− mice.
First, we found that He−/− mice displayed a remarkable lower
body weight detected almost since they were born, a variable that
was never recovered in adult mice. Low birth weight has been
strongly associated with schizophrenia and with worse social
and cognitive abilities in these patients (Rifkin et al., 1994).
Lower body weight has also been described even in adult patients
until they suffer the first episode (Wetterling et al., 2004). In
contrast, after this first episode, schizophrenic patients suffer a
remarkable increase of body weight (Holt et al., 2018) due, at
least in part, to chronic antipsychotic treatments (Baptista, 1999).
Regarding to the striatal-dependent alterations, we previously
observed that He−/− mice show subtle alterations in motor skills
(Martín-Ibáñez et al., 2017) as occurs in schizophrenic patients
(Wolff and O’Driscoll, 1999), which was related to an altered
striatal function, although a role of the cerebellum should not
be ruled out. Here we have increased such previous data by
describing an aberrant impulsive behavior associated with an
increase of the spine density in MSNs in the same line as occurs
with schizophrenic patients (Glausier and Lewis, 2013; Hoptman,
2015). Surprisingly, He−/− mice did show increased agitation
(locomotor activity) upon amphetamine injection but not upon
apomorphine injection, suggesting that Helios deficiency could
be preferentially involved with negative symptomatology and
just moderately with positive symptomatology (Powell and
Miyakawa, 2006) or alternatively, that Helios deficiency partially
impacts the dopaminergic system. Finally, it is noteworthy that
the observed increase of spine density in MSNs in He−/− mice
also occurs in schizophrenic patients and correlate with negative
and cognitive symptoms (Roberts et al., 2005, 2008).
Regarding the hippocampal-related phenotype, we recently
described that He−/− mice display hippocampal-dependent
spatial learning and memory impairments associated with
alterations in synaptic plasticity (Giralt et al., 2019). The findings
described here include decreased density and size of PSD-
95 clusters in the CA1, altered maternal-filial social behavior,
and severe social novelty/memory impairments in He−/− mice.
Decreased PSD-95 levels have been described in the CA1 of
schizophrenic patients (Matosin et al., 2016). Indeed, decreased
PSD-95 levels is one of the most consistent synaptic alterations
in the hippocampus from patients as recently summarized
in a broad metanalysis (Osimo et al., 2019). Patients with
schizophrenia also show consistent deficits in spatial working
memory and social skills (Brüne et al., 2011). Such alterations
could be perfectly associated to an hippocampal dysfunction
since this brain region modulates socio-cognitive skills and
spatial memory (Shrager et al., 2007; Rubin et al., 2014).
In line with this, it is noteworthy that the hippocampus is
morphologically the most affected brain region in schizophrenia
(Mancini et al., 2019).
A potential mechanism of the schizophrenia-like phenotype
observed in He−/− mice could be the sustained increase on
WDFY1 levels in different core brain regions implicated in
schizophrenia. First, because it is the only gene that remains
altered in different brain regions from the RNAseq experiment
performed in our previous study at embryonic day 18 (Giralt
et al., 2019). Second, because WDFY1 is upregulated in the
hippocampus and dorso-lateral prefrontal cortex of patients
with schizophrenia and in the hippocampus and striatum of
He−/− mice. Although our pharmacological treatments with
LPS and Poly I:C do not induce changes on WDFY1 levels,
we hypothesize that the sustained increase of WDFY1 levels
in He−/− mice and schizophrenia patients could be due to an
impairment of a proper neuroimmunomodulation that may have
its origin in the early phases of the neurodevelopment, when
Helios is specifically expressed (Martín-Ibáñez et al., 2012, 2017).
The hypothesized impairment in the neuroimmunomodulation
could be provoked by molecular changes involving the Helios-
dependent pathway. The fact that Helios is a potent regulator of
molecular pathways related to immunity (Heizmann et al., 2018)
strengthens our hypothesis.
In this line, since we detected a persistent upregulation
of WDFY1 in the CA1 pyramidal cells of He−/− mice, we
expected a resulting increase on neuronal NF-κB expression
(Hanke and Kielian, 2011; Okun et al., 2011) as previously
described in other cell types (Hu et al., 2015). Conversely,
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FIGURE 4 | Characterization of schizophrenia-like phenotypes related to hippocampal function in He−/− mice. (A) Latency (in seconds) to reach the maternal area
in He+/+ and He−/− mice at postnatal day 10 (left, n = 3 He+/+ males and 6 He+/+ females, and 3 He−/− males and 4 He−/− females) and postnatal day 14
(right, n = 3 He+/+ males and 4 He+/+ females, and 3 He−/− males and 3 He−/− females). (B) Time exploring the mouse (stranger 1) and empty (empty) cages
during socialization in the three-chamber sociability test in 8-week-old He+/+ and He−/− mice (n = 6 He+/+ and 6 He−/−; 3 males and 3 females per genotype).
(C) Time exploring the known (stranger 1) and the stranger mouse (stranger 2) cages in the social memory and novelty preference evaluation of the three-chamber
sociability test in 8-weeks-old He+/+ and He−/− mice. (D) Representative inset (17 × 9 microns) of confocal images immunostained for PSD-95 in CA1 stratum
radiatum (63x objective, digital zoom 5). Original area of analysis per field was 65 × 65 microns. For this experiment, 8-week-old He+/+ and He−/− mice (n = 2
He+/+ males and 3 He+/+ females, and 2 He−/− males and 3 He−/− females) were used. Scale bar = 10 microns. Quantification of the number (E) and size (F) of
PSD-95-positive puncta per field. Bars represent mean ± SEM. Data were analyses by Student’s t-test in (A,E,F) and by two-way ANOVA with the Bonferroni’s
post hoc test in (B,C). *p < 0.05, **p < 0.01 when compared with He+/+ mice in (A,E,F). ***p < 0.001 when compared with “empty” in (B) or “stranger 1” in (C).
we observed a reduced NF-κB (p65) expression in the cell
bodies/nuclei of these CA1 pyramidal cells, which could suggest
a decrease in the ability of NF-κB to activate transcription.
There could be some potential explanations for these apparently
contradictory results. First, in the previous work by Hu et al.
(2015) the authors observed in 293-TLR3 cells a potentiated
NF-κB activation by WDFY1 only in stimulation conditions
of the TLR3/4 receptors but not in basal conditions. The
proposed mechanism was the recruitment of TRIF by WDFY1.
Thereby, we hypothesize that increased WDFY1 levels without
immunologic stimulation (present results) does not necessarily
potentiate the NF-κB signaling/levels. Second, the dynamics
and functions of the WDFY1:NF-κB pathway is completely
unknown in neuronal cells and the potential interactors with
WDFY1 in neurons is an open field to deepen on in future
studies. Thus, it is widely accepted that in peripheral or in glial
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FIGURE 5 | Levels and distribution of DISC1 and NF-κB in the hippocampus of He−/− mice. (A) Immunoblotting for DISC1 and Tubulin as a loading control in the
striatum (Str, n = 9/genotype) or hippocampus (Hipp, n = 10–11/genotype) of 8-week-old He+/+ and He−/− mice. Densitometry quantification in the striatal (B) and
hippocampal (C) samples of results as in (A). Data were normalized to tubulin for each sample and expressed as percentage of wild type. (D) Representative
confocal images of NF-κB immunofluorescence in CA1 (40x objective) of 8-week-old He+/+ and He−/− mice (n = 10 He+/+ and 8 He−/−). Scale bar = 70 microns.
(E) Quantification of NF-κB the IOD per layer (total IOD mean per layer). Bars represent mean ± SEM. Data were analyzed by Student’s t-test. ***p < 0.001 when
compared with He+/+ mice in (E).
cells, NF-κB activation induces inflammatory or pro-apoptotic
pathways and responses via nuclear translocation as a main
but not the only mechanism (Liu et al., 2017). However, the
role of NF-κB in neurons seems to be more oriented to the
modulation of synaptic plasticity and cognitive processes such
as learning and memory (Meffert et al., 2003; Dresselhaus and
Meffert, 2019). Furthermore, NF-κB is a main transcriptional
inductor of PSD-95 expression (Boersma et al., 2011) which
is consistent with our findings of the localized reduction of
the scaffold protein in the CA1 of mice devoid of Helios.
Finally, although some previous studies have shown that NF-
κB is increased in peripheral cells of schizophrenic patients
(Song et al., 2009), studies evaluating brain post-mortem samples
showed a significant decrease of NF-κB expression in cerebellum
(MacDowell et al., 2017), dorsolateral prefrontal cortex, and
temporal area gyrus (Roussos et al., 2013). Altogether, these
results indicate a decrease in the ability of NF-κB to activate
transcription and are in accordance with different potential roles
and distinct mechanisms of regulation of NF-κB depending
on the tissue to be analyzed and, in turn, strengthen our
hypothesis that reduced NF-κB in CA1 pyramidal neurons could
play a role in the schizophrenic-like phenotype observed in
He−/− mice.
Yet our study has some limitations. First, the finding that
the Wdfy1 gene is upregulated in the hippocampus of He−/−
mice could be indirect since no direct evidence of transcription
control of Wdfy1 by Helios has been previously observed in
literature using microarrays or Chip-seq approaches (Kim et al.,
2015; Zhao et al., 2016) in tissues other than nervous system.
Similar lack of direct evidence was obtained when searching in
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FIGURE 6 | WDFY1 protein levels in pharmacological models of schizophrenia. (A) Immunoblotting for WDFY1 and Tubulin as a loading control in the striatum (Str)
and hippocampus (Hipp) of 10-week-old C57BL/6 mice treated with vehicle or amphetamine (3 mg/kg) or ketamine (30 mg/kg) for 8 days (n = 8 vehicle- (Veh), 10
ketamine- (Keta) and 11 amphetamine-treated (Amph) mice). (B) Densitometry quantification of results as in (A). Data were normalized to tubulin for each sample
and expressed as percentage of wild type. (C) Immunoblotting for WDFY1 and Tubulin as a loading control in the striatum (Str), frontal cortex (FCtx) and
hippocampus (Hipp) of C57BL/6 mice treated at postnatal day 5 with vehicle or LPS (6 mg/kg) or Poly I:C (6 mg/kg) and samples collected 24 h later (n = 9 vehicle-
(Veh), 6 LPS- and 7 Poly I:C-treated mice). (D) Densitometry quantification of results as in (C). Data were normalized to tubulin for each sample and expressed as
percentage of wild type. Bars represent mean ± SEM. Data were analyzed by one-way ANOVA and the Tukey’s test as a post hoc test in all panels.
public databases such as GEO1 or Harmonizome2. In line with
this, although in the present manuscript we have analyzed all the
genes differentially expressed in the RNAseq experiment from
our previous study (Giralt et al., 2019) and we found that only
Wdfy1 was still upregulated, our previous RNAseq was performed
1https://omictools.com/a1ae9227ffba28725cba03e44b02aee1-dataset
2http://amp.pharm.mssm.edu/Harmonizome/gene/WDFY1
in embryonic hippocampal tissue at E18 (Giralt et al., 2019). As
a consequence, we cannot rule out that other unexplored genes
are differentially expressed in the adult neural tissue of He−/−
mice that could also be involved with the psychiatric disturbances
described here. Finally, although Helios (Martín-Ibáñez et al.,
2012, 2017; Giralt et al., 2019) and WDFY1 (present results3)
3https://mouse.brain-map.org/gene/show/45210
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are enriched in neurons, increased WDFY1 levels could exert
an alternative cell-non-autonomous effect since TLR receptors
are mostly expressed in glia (Kielian, 2006) whereas they are
expressed in a lesser extent in neurons (Hanke and Kielian, 2011;
Okun et al., 2011).
Taken altogether, we propose the He−/− mice as a model
to study how alterations during the development of the central
nervous system could account for molecular pathways typically
involved with immunomodulatory processes that would later
precipitate the appearance of neuropsychiatric disorders such as
schizophrenic pathology.
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